The Atopic Dermatitis market and the approval of Dupixent
Slides in the pack:
- Dupixent, a new biologic targeting severe Atopic Dermatitis from Sanofi and Regeneron has been approved by the FDA (March 2017)
- The SOLO 1 and SOLO 2 Trials strongly affirmed Dupixent’s utility in moderate – severe AD
- Epidemiology and market size for Atopic Dermatitis
- Landscape of classical treatments for Atopic Dermatitis
- Recently launched drugs and pipeline for Atopic Dermatitis
- The payer negotiation strategies adopted by Sanofi and Regeneron for Dupixent
Reviews
There are no reviews yet.